NASDAQ:GDRX GoodRx (GDRX) Stock Price, News & Analysis → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free GDRX Stock Alerts $7.87 +0.31 (+4.10%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$7.50▼$7.9050-Day Range$6.50▼$8.0652-Week Range$4.14▼$9.37Volume1.12 million shsAverage Volume1.76 million shsMarket Capitalization$2.95 billionP/E RatioN/ADividend YieldN/APrice Target$9.11 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get GoodRx alerts: Email Address GoodRx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.55 Rating ScoreUpside/Downside15.7% Upside$9.11 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.23Based on 15 Articles This WeekInsider TradingN/AProj. Earnings Growth47.06%From $0.17 to $0.25 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.50 out of 5 starsMedical Sector514th out of 928 stocksData Processing & Preparation Industry35th out of 60 stocks 3.3 Analyst's Opinion Consensus RatingGoodRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on 12 buy ratings, 7 hold ratings, and 1 sell rating.Amount of Analyst CoverageGoodRx has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about GoodRx's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GDRX. Previous Next 0.0 Dividend Strength Dividend YieldGoodRx does not currently pay a dividend.Dividend GrowthGoodRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GDRX. Previous Next 2.4 News and Social Media Coverage News SentimentGoodRx has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for GoodRx this week, compared to 5 articles on an average week.Search Interest14 people have searched for GDRX on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added GoodRx to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GoodRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.17% of the stock of GoodRx is held by insiders.Percentage Held by Institutions63.77% of the stock of GoodRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GoodRx's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for GoodRx are expected to grow by 47.06% in the coming year, from $0.17 to $0.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GoodRx is -786.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GoodRx is -786.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioGoodRx has a PEG Ratio of 3.67. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGoodRx has a P/B Ratio of 4.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about GoodRx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe Worst is Yet to Come…Millions of Unsuspecting Americans Could be Wiped Out… Yet those who watch this bombshell exposé and prepare before it’s too late could have the chance to protect their financial future and grow their wealth significantly.Click here to stream this controversial exposé now. About GoodRx Stock (NASDAQ:GDRX)GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.Read More GDRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GDRX Stock News HeadlinesMay 31 at 10:40 AM | prnewswire.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GoodRxMay 30 at 4:05 PM | businesswire.comSimon Patterson Joins GoodRx Board of DirectorsMay 30 at 2:51 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against GoodRx Holdings, Inc. - GDRXMay 30 at 8:35 AM | businesswire.comGoodRx Named One of the 2024 TIME100 Most Influential CompaniesMay 30 at 6:45 AM | prnewswire.comLevi & Korsinsky Reminds GoodRx Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 21, 2024 - GDRXMay 29, 2024 | prnewswire.comShareholders that lost money on GoodRx Holdings, Inc.(GDRX) should contact The Gross Law Firm about pending Class Action - GDRXMay 29, 2024 | markets.businessinsider.comIMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Encourages Investors in GoodRx Holdings, Inc. with Losses to Contact the FirmMay 28, 2024 | prnewswire.comROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages GoodRx Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GDRXMay 28, 2024 | prnewswire.comGDRX Investors Have Opportunity to Lead GoodRx Holdings, Inc. Securities Fraud LawsuitMay 28, 2024 | seekingalpha.comGoodRx: Encouraging Profit Stabilization (Rating Upgrade)May 27, 2024 | markets.businessinsider.comGoodRx Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - GDRXMay 27, 2024 | stockhouse.comONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GoodRxMay 27, 2024 | prnewswire.comGDRX Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges GDRX Investors with Losses to Contact the FirmMay 25, 2024 | americanbankingnews.comGoodRx (NASDAQ:GDRX) Shares Gap Up to $7.20May 24, 2024 | markets.businessinsider.comShareholders Who Lost Money on GoodRx Holdings, Inc.(GDRX) should contact Levi & Korsinsky about pending Class Action - GDRXMay 24, 2024 | prnewswire.comGDRX Investors Have Opportunity to Lead GoodRx Holdings, Inc. Securities Fraud LawsuitMay 24, 2024 | americanbankingnews.comGoodRx (NASDAQ:GDRX) Rating Increased to Outperform at Royal Bank of CanadaMay 23, 2024 | msn.comRBC Capital raises GoodRx to outperform, cites growth opportunitiesMay 23, 2024 | msn.comRBC Capital Upgrades GoodRx Holdings (GDRX)May 23, 2024 | markets.businessinsider.comGoodRx Holdings Sell Rating: Navigating Strategic Shifts and Industry TrendsMay 23, 2024 | markets.businessinsider.comInvestors who lost money on GoodRx Holdings, Inc. (GDRX) should contact Levi & Korsinsky about pending Class Action - GDRXMay 23, 2024 | prnewswire.comContact Levi & Korsinsky by June 21, 2024 Deadline to Join Class Action Against GoodRx Holdings, Inc. (GDRX)May 22, 2024 | businesswire.comGoodRx Offers Discounts of Up to 43% On Fertility TreatmentsMay 21, 2024 | prnewswire.comROSEN, LEADING INVESTOR COUNSEL, Encourages GoodRx Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GDRXMay 21, 2024 | prnewswire.comGDRX Investors Have Opportunity to Lead GoodRx Holdings, Inc. Securities Fraud LawsuitSee More Headlines Receive GDRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GoodRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/02/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Data processing & preparation Sub-IndustryN/A Current SymbolNASDAQ:GDRX CUSIPN/A CIK1809519 Webwww.goodrx.com Phone855-268-2822FaxN/AEmployees694Year FoundedN/APrice Target and Rating Average Stock Price Target$9.11 High Stock Price Target$16.00 Low Stock Price Target$4.50 Potential Upside/Downside+15.7%Consensus RatingModerate Buy Rating Score (0-4)2.55 Research Coverage20 Analysts Profitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E Ratio46.29 P/E Growth3.52Net Income$-8,870,000.00 Net Margins-0.86% Pretax Margin-7.70% Return on Equity3.45% Return on Assets1.70% Debt Debt-to-Equity Ratio1.02 Current Ratio6.29 Quick Ratio6.29 Sales & Book Value Annual Sales$750.27 million Price / Sales3.94 Cash Flow$0.43 per share Price / Cash Flow18.31 Book Value$1.68 per share Price / Book4.68Miscellaneous Outstanding Shares375,200,000Free Float359,559,000Market Cap$2.95 billion OptionableOptionable Beta1.37 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Trevor Bezdek (Age 46)Co-founder & Chairman Comp: $537kMr. Douglas Joseph Hirsch (Age 53)Co-founder, Chief Mission Officer & Director Comp: $507.29kMr. Karsten Ian Voermann (Age 54)CFO & Principal Financial Officer Comp: $693.69kMr. Romin Nabiey (Age 36)Chief Accounting Officer & Principal Accounting Officer Comp: $516kMr. Scott W. Wagner (Age 53)Interim CEO & Principal Operating Officer Mr. Mike WalshPresident & Executive VP of Prescription MarketplaceMs. Whitney NotaroVice President of Investor RelationsMs. Gracye ChengGeneral Counsel & SecretaryMr. Andrew Slutsky (Age 37)Chief Marketing Officer Comp: $864.8kMs. Vina M. Leite (Age 54)Chief People Officer More ExecutivesKey CompetitorsDada NexusNASDAQ:DADAZendeskNYSE:ZENToastNYSE:TOSTRedditNYSE:RDDTGlobantNYSE:GLOBView All CompetitorsInsiders & InstitutionsWalleye Trading LLCSold 21,800 shares on 5/17/2024Ownership: 0.000%Beacon Capital Management LLCBought 4,000 shares on 5/17/2024Ownership: 0.001%California State Teachers Retirement SystemBought 3,444 shares on 5/16/2024Ownership: 0.018%Bayesian Capital Management LPSold 27,100 shares on 5/16/2024Ownership: 0.004%EntryPoint Capital LLCBought 11,548 shares on 5/14/2024Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions GDRX Stock Analysis - Frequently Asked Questions Should I buy or sell GoodRx stock right now? 20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GoodRx in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GDRX shares. View GDRX analyst ratings or view top-rated stocks. What is GoodRx's stock price target for 2024? 20 analysts have issued 1 year price objectives for GoodRx's shares. Their GDRX share price targets range from $4.50 to $16.00. On average, they expect the company's share price to reach $9.11 in the next year. This suggests a possible upside of 15.7% from the stock's current price. View analysts price targets for GDRX or view top-rated stocks among Wall Street analysts. How have GDRX shares performed in 2024? GoodRx's stock was trading at $6.70 at the beginning of the year. Since then, GDRX shares have increased by 17.5% and is now trading at $7.87. View the best growth stocks for 2024 here. When is GoodRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our GDRX earnings forecast. How were GoodRx's earnings last quarter? GoodRx Holdings, Inc. (NASDAQ:GDRX) posted its earnings results on Thursday, May, 9th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by $0.01. The firm earned $197.88 million during the quarter, compared to the consensus estimate of $196.20 million. GoodRx had a negative net margin of 0.86% and a positive trailing twelve-month return on equity of 3.45%. What ETFs hold GoodRx's stock? ETFs with the largest weight of GoodRx (NASDAQ:GDRX) stock in their portfolio include WisdomTree Growth Leaders Fund (PLAT), Fidelity Digital Health ETF (FDHT) and Global X Telemedicine & Digital Health ETF (EDOC).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG). What guidance has GoodRx issued on next quarter's earnings? GoodRx updated its FY 2024 earnings guidance on Thursday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $800.0 million-$810.0 million, compared to the consensus revenue estimate of $801.0 million. What other stocks do shareholders of GoodRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other GoodRx investors own include Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY), DraftKings (DKNG), GW Pharmaceuticals (GWPH), Rocket Companies (RKT), AT&T (T), Advanced Micro Devices (AMD) and Alteryx (AYX). When did GoodRx IPO? GoodRx (GDRX) raised $900 million in an IPO on Wednesday, September 23rd 2020. The company issued 34,600,000 shares at a price of $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays served as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers. Who are GoodRx's major shareholders? GoodRx's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.05%), Assenagon Asset Management S.A. (0.26%), Picton Mahoney Asset Management (0.12%), GSA Capital Partners LLP (0.06%), Susquehanna Portfolio Strategies LLC (0.05%) and Mirae Asset Global Investments Co. Ltd. (0.05%). Insiders that own company stock include Abdiel Capital Management, Llc, Agnes Rey-Giraud, Andrew Slutsky, Babak Azad, Bansi Nagji, Douglas Joseph Hirsch, Idea Men, Llc, Karsten Voermann, Scott Wagner and Trevor Bezdek. View institutional ownership trends. How do I buy shares of GoodRx? Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GDRX) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GoodRx Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
